Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebastine vs Mebeverine in Irritable Bowel Syndrome
NCT05815602Phase 3Active, not recruiting
- Start
- Mar 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eribulin in irritable bowel syndrome (IBS). Started Mar 2023; status: active, not recruiting.
02
Drugs
eribulin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT05815602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815602.